Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?

We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial T(H)1 anticancer immune responses while suppressing the un...

Descripción completa

Detalles Bibliográficos
Autores principales: Swarbrick, Alexander, Junankar, Simon R, Batten, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782520/
https://www.ncbi.nlm.nih.gov/pubmed/24083081
http://dx.doi.org/10.4161/onci.25409
_version_ 1782285568673054720
author Swarbrick, Alexander
Junankar, Simon R
Batten, Marcel
author_facet Swarbrick, Alexander
Junankar, Simon R
Batten, Marcel
author_sort Swarbrick, Alexander
collection PubMed
description We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial T(H)1 anticancer immune responses while suppressing the unwanted accumulation of regulatory T cells.
format Online
Article
Text
id pubmed-3782520
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-37825202013-09-30 Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy? Swarbrick, Alexander Junankar, Simon R Batten, Marcel Oncoimmunology Author's View We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial T(H)1 anticancer immune responses while suppressing the unwanted accumulation of regulatory T cells. Landes Bioscience 2013-08-01 2013-07-01 /pmc/articles/PMC3782520/ /pubmed/24083081 http://dx.doi.org/10.4161/onci.25409 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Swarbrick, Alexander
Junankar, Simon R
Batten, Marcel
Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
title Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
title_full Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
title_fullStr Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
title_full_unstemmed Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
title_short Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
title_sort could the properties of il-27 make it an ideal adjuvant for anticancer immunotherapy?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782520/
https://www.ncbi.nlm.nih.gov/pubmed/24083081
http://dx.doi.org/10.4161/onci.25409
work_keys_str_mv AT swarbrickalexander couldthepropertiesofil27makeitanidealadjuvantforanticancerimmunotherapy
AT junankarsimonr couldthepropertiesofil27makeitanidealadjuvantforanticancerimmunotherapy
AT battenmarcel couldthepropertiesofil27makeitanidealadjuvantforanticancerimmunotherapy

Ejemplares similares